Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)

Cerebral Cavernous Malformation Clinical Trial

Official title:
Functional Magnetic Resonance Imaging (fMRI) Vascular Reactivity in Cerebral Cavernous Malformations (CCM)

Status Recruiting

Clinical Trial Summary

The goal is to characterize vascular reactivity and cardiac pulsatility of normal appearing white matter in patients with CCM during hypercarbia/hypocarbia using quantitative real-time high-speed multi-echo fMRI to develop prognostic biomarkers for CCM formation

Clinical Trial Description

n/a

Study Design

Related Conditions & MeSH terms

Clinical Trial Details

NCT number	NCT05298709
Study type	Interventional
Source	University of New Mexico
Contact	Michel Tobey, MD
Phone	(505) 272-3152
Email	MTorbey@salud.unm.edu
Status	Recruiting
Phase	N/A
Start date	June 15, 2023
Completion date	June 28, 2025

View Details

See also
Status	Clinical Trial	Phase
Recruiting	`NCT04467489` - Biomarkers of CASH
Active, not recruiting	`NCT05085561` - The Symptomatic Cerebral Cavernous Malformation Trial of REC-994	Phase 2
Active, not recruiting	`NCT02946866` - CoHOrt of Cerebral CavernOus maLformATion: multicEnter Prospective Observational Study
Active, not recruiting	`NCT02603328` - Atorvastatin Treatment of Cavernous Angiomas With Symptomatic Hemorrhage Exploratory Proof of Concept (AT CASH EPOC) Trial	Phase 1/Phase 2
Terminated	`NCT05148663` - CCM Blood Biomarker Validation Study
Completed	`NCT03652181` - CASH (Cavernous Angiomas With Symptomatic Hemorrhage) Trial Readiness
Completed	`NCT03589014` - Treat_CCM: Propranolol in Familial Cerebral Cavernous Malformation	Phase 2